| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794907 | Ophthalmology Retina | 2017 | 7 Pages |
Abstract
After the switch in therapy from ranibizumab to aflibercept, visual acuity remained stable for >12 months in both groups. Nevertheless, eyes that required frequent reinjections under ranibizumab also had a higher treatment demand under aflibercept.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Justus G. MD, Hanna Maria Russ, Isabel B. Pfister,